InMed Pharmaceuticals (INM)
(Delayed Data from NSDQ)
$2.24 USD
0.00 (-0.20%)
Updated Aug 8, 2025 10:42 AM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
INM 2.24 0.00(-0.20%)
Will INM be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for INM based on the 1-3 month trading system that more than doubles the S&P 500.
Other News for INM
InMed to Present INM-901 Data at Alzheimer's Association International Conference (AAIC) 2025 | ...
InMed Pharmaceuticals (INM) Files to Sell 3.9 Million Common Shares | INM Stock News
InMed Pharmaceuticals registers 3.9M shares for resale
InMed Pharmaceuticals files to sell 3.9M common shares for holders
InMed Pharmaceuticals Secures $5 Million in Private Placement to Advance Drug Pipeline